[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100627087":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":22,"locations":31,"responsibleParty":53,"collaborators":56,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":10,"studyType":71,"phases":10,"briefSummary":72,"conditions":73,"keywords":76,"overallStatus":88,"whyStopped":10,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"National University of Singapore","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"NOVI Health weight management cohort",null,"Adults newly enrolled in the NOVI Health weight management program receiving standard-of-care GLP-1 receptor agonist therapy (semaglutide or tirzepatide) and lifestyle coaching (diet and physical activity) as part of routine clinical care. Medication type is determined by routine clinical care and patient-clinician decision-making, not by the research study.",[13],"Other: Not applicable. This is an observational study.",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"Not applicable. This is an observational study.",[9],[19],{"name":20,"affiliation":5,"role":21},"Jan Gruber, PhD","PRINCIPAL_INVESTIGATOR",[23,28],{"name":24,"role":25,"phone":26,"phoneExt":10,"email":27},"Zhi Meng Lim, MSc","CONTACT","+65 90084510","zmlim@nus.edu.sg",{"name":29,"role":25,"phone":10,"phoneExt":10,"email":30},"Hui Ching Michelle Lee, PhD","michelle.lee@novi-health.com",[32,48],{"facility":33,"status":10,"city":34,"state":10,"zip":35,"country":34,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"NOVI Health (T3 Health PTE LTD)","Singapore","068914",{"type":37,"coordinates":38},"Point",[39,40],103.85007,1.28967,{"lat":40,"lon":39},[43,45],{"name":29,"role":25,"phone":44,"phoneExt":10,"email":30},"+65 82822765",{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Sue-Anne Ee Shiow Toh, MA MBBChir MSc","SUB_INVESTIGATOR",{"facility":5,"status":10,"city":34,"state":10,"zip":49,"country":34,"cosmosGeoPoint":50,"geoPoint":52,"contacts":10},"119077",{"type":37,"coordinates":51},[39,40],{"lat":40,"lon":39},{"type":21,"investigatorFullName":54,"investigatorTitle":55,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Jan Gruber","Associate Professor",[57],{"name":58,"class":59},"T3 Health PTE LTD","UNKNOWN","100627087",false,"NCT07444073","Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock","Inclusion Criteria\n\n* Adults aged 40-89 years, who are newly enrolled in the NOVI OP+ weight management program.\n* BMI of ≥ 30 kg\u002Fm2 (obesity); OR\n* BMI of ≥ 27 kg\u002Fm2 to \\\u003C 30 kg\u002Fm2 (overweight) in the presence of at least one weight-related comorbid condition e.g. dysglycemia (prediabetes or type 2 diabetes mellitus), hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease.\n\nExclusion Criteria\n\n* Pregnancy or lactation.\n* Non-ambulatory status, total blindness, complete hearing loss, or inability to speak.\n* Medical history of, or self-reported, psychiatric illness, congenital or irreversible neurodegenerative diseases, cognitive impairment, or eating disorders that may affect adherence or assessment outcomes.\n* On GLP-1 RA, sulfonylurea or insulin medications for the past 3 months.\n* Active cancer on chemotherapy or immunotherapy.\n* Known hypersensitivity or contraindications to GLP-1 RAs.\n* Any condition, in the opinion of the attending clinician, that would jeopardize participant safety or interfere with study compliance.","ALL","40 Years","89 Years",{"count":69,"type":70},440,"ESTIMATED","OBSERVATIONAL","This study examines whether routine treatment with semaglutide or tirzepatide, prescribed with lifestyle coaching in a real-world weight-management program, is associated with changes in biological age measured by the LinAge2 clinical aging clock over 6 months.",[74,75],"Aging","Obesity & Overweight",[77,78,79,80,81,82,83,84,85,86,87],"LinAge2","Biological Age","GLP-1 Receptor Agonist","Semaglutide","Tirzepatide","Weight Management Program","Lifestyle","Real-World Evidence","Cardiometabolic Biomarkers","Body Composition","Prospective Cohort","NOT_YET_RECRUITING","2026-06-29",{"date":91,"type":92},"2026-07-01","ACTUAL",{"date":94,"type":70},"2026-06-01",{"date":96,"type":70},"2027-12-31",{"name":5,"class":6},2]